Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

Authors
Category Primary study
JournalCurr. Ther. Res. Clin. Exp.
Year 2026
This article has no abstract
Epistemonikos ID: 0d960e5ca8ad808cbf9d7d03abde81ed30f401c4
First added on: Apr 04, 2026